These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 18588461)

  • 21. A molecular fingerprint for medulloblastoma.
    Lee Y; Miller HL; Jensen P; Hernan R; Connelly M; Wetmore C; Zindy F; Roussel MF; Curran T; Gilbertson RJ; McKinnon PJ
    Cancer Res; 2003 Sep; 63(17):5428-37. PubMed ID: 14500378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medulloblastoma molecular dissection: the way toward targeted therapy.
    Remke M; Ramaswamy V; Taylor MD
    Curr Opin Oncol; 2013 Nov; 25(6):674-81. PubMed ID: 24076581
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays.
    Kagawa N; Maruno M; Suzuki T; Hashiba T; Hashimoto N; Izumoto S; Yoshimine T
    Brain Tumor Pathol; 2006 Apr; 23(1):41-7. PubMed ID: 18095118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medulloblastoma.
    Padovani L; André N; Gentet JC; Muracciole X
    Eur J Cancer; 2011 Sep; 47 Suppl 3():S338. PubMed ID: 21944006
    [No Abstract]   [Full Text] [Related]  

  • 25. Classic and desmoplastic medulloblastoma: complete case reports and characterizations of two new cell lines.
    Holthouse DJ; Dallas PB; Ford J; Fabian V; Murch AR; Watson M; Wong G; Bertram C; Egli S; Baker DL; Kees UR
    Neuropathology; 2009 Aug; 29(4):398-409. PubMed ID: 19077040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Signaling pathway deregulation and molecular alterations across pediatric medulloblastomas.
    Lhermitte B; Blandin AF; Coca A; Guerin E; Durand A; Entz-Werlé N
    Neurochirurgie; 2021 Feb; 67(1):39-45. PubMed ID: 29776650
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Past, current and future protocols for combined modality therapy in childhood medulloblastoma.
    Kaaijk P; Schouten-van Meeteren AY; Slotman BJ; Kaspers GJ
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):79-90. PubMed ID: 12597352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histologic features and prognosis in pediatric medulloblastoma.
    Verma S; Tavaré CJ; Gilles FH
    Pediatr Dev Pathol; 2008; 11(5):337-43. PubMed ID: 18201118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New concepts in organ site research on medulloblastoma: genetics and genomics.
    Roussel MF
    Future Oncol; 2010 Aug; 6(8):1229-31. PubMed ID: 20799868
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma.
    Lo KC; Ma C; Bundy BN; Pomeroy SL; Eberhart CG; Cowell JK
    Clin Cancer Res; 2007 Dec; 13(23):7022-8. PubMed ID: 18056178
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Medulloblastoma: towards new prognostic factors].
    San-Galli F; Maire JP; Guérin J
    Neurochirurgie; 1991; 37(1):3-11. PubMed ID: 2017290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of microRNAs in medulloblastoma.
    Vidal DO; Marques MM; Lopes LF; Reis RM
    Pediatr Hematol Oncol; 2013 Aug; 30(5):367-78. PubMed ID: 23528184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of and prognosis with medulloblastoma: therapy at a crossroads.
    Packer RJ; Vezina G
    Arch Neurol; 2008 Nov; 65(11):1419-24. PubMed ID: 19001159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis.
    Kim W; Choy W; Dye J; Nagasawa D; Safaee M; Fong B; Yang I
    J Clin Neurosci; 2011 Jul; 18(7):886-90. PubMed ID: 21640908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-level copy gain versus amplification of myc oncogenes in medulloblastoma: utility in predicting prognosis and survival. Laboratory investigation.
    Takei H; Nguyen Y; Mehta V; Chintagumpala M; Dauser RC; Adesina AM
    J Neurosurg Pediatr; 2009 Jan; 3(1):61-5. PubMed ID: 19119907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term neuromotor speech deficits in survivors of childhood posterior fossa tumors: effects of tumor type, radiation, age at diagnosis, and survival years.
    Huber JF; Bradley K; Spiegler B; Dennis M
    J Child Neurol; 2007 Jul; 22(7):848-54. PubMed ID: 17715277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical management of medulloblastoma in adults.
    Eisenstat DD
    Expert Rev Anticancer Ther; 2004 Oct; 4(5):795-802. PubMed ID: 15485314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma.
    Ramaswamy V; Northcott PA; Taylor MD
    Cancer Genet; 2011 Nov; 204(11):577-88. PubMed ID: 22200083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging treatments and gene expression profiling in high-risk medulloblastoma.
    Sardi I; Cavalieri D; Massimino M
    Paediatr Drugs; 2007; 9(2):81-96. PubMed ID: 17407364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.